Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 8—August 2004

Research

Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000

Dominique L. Monnet*, Fiona M. MacKenzie†Comments to Author , José María López-Lozano‡, Arielle Beyaert§, Máximo Camacho§, Rachel Wilson†, David Stuart†, and Ian M. Gould†
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark; †Aberdeen Royal Infirmary, Aberdeen, Scotland; ‡Hospital Vega Baja, Orihuela (Alicante), Spain; §University of Murcia, Murcia, Spain

Main Article

Table 1

Antimicrobial drug coresistance in methicillin-resistant Staphylococcus aureus (MRSA) isolates and in methicillin-susceptible S. aureus (MSSA), Aberdeen Royal Infirmary, 1997–2000

Antimicrobial drug MRSA isolates
MSSA isolates
Risk ratio p value
No. tested for coresistance No. resistant (%) No. tested for coresistance No. resistant (%)
Ciprofloxacin
1,218
1,195 (98.1)
515
183 (35.5)
13.4
< 0.0001
Clindamycin
2,722
2,666 (97.9)
7,715
956 (12.4)
89.6
< 0.0001
Erythromycin
2,721
2,669 (98.1)
7,701
1,115 (14.5)
90.0
< 0.0001
Fusidic acid
2,736
36 (1.3)
7,798
636 (8.2)
0.20
< 0.0001
Gentamicin
1,350
11 (0.8)
3,276
44 (1.3)
0.68
NSa
Mupirocin
2,514
154 (6.1)
5,180
99 (1.9)
1.92
< 0.0001
Rifampin
1,005
62 (6.2)
72
8 (11.1)
0.95
NS
Tetracycline
997
109 (10.9)
468
94 (20.1)
0.76
< 0.0001
Trimethoprim 1,060 18 (1.7) 0

aNS, nonsignificant.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO